



November 30, 2022

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code: 506943**

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub: JB Chemicals & Pharmaceuticals Limited (JB Pharma) receives ANDA approval for Venlafaxine Hydrochloride Extended-Release Tablets from USFDA**

This is to inform you that JB Pharma has received ANDA approval from the USFDA for Venlafaxine Extended Release Tablets 37.5mg, 75mg, 150mg and 225mg. This product is based on OROS (Osmotic Controlled Release Oral Delivery System) technology, an advanced and precision-controlled release mechanism. The generic product approval is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Venlafaxine Hydrochloride Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, of Osmotica Pharmaceutical U.S. LLC.

As per IQVIA Health MAT Oct 2022 data, Venlafaxine Extended-Release tablets recorded annualized sales of approximately \$ 48 million in the US.

We request you to take the above announcement on record.

Thanking You,

Yours faithfully,

**For J.B. Chemicals & Pharmaceuticals Ltd.**

**Sandeep Phadnis**  
**Vice President – Secretarial & Company Secretary**

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Nergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500